FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2969882767> ?p ?o ?g. }

• W2969882767 endingPage "2411" @default.
• W2969882767 startingPage "2411" @default.
• W2969882767 abstract "Abstract Introduction: Up to 90% of MDS patients require red blood cell (RBC) transfusions and 30-45% become RBC transfusion dependent (RBC-TD). However, literature addressing RBC alloimmunisation in MDS is limited. This study evaluates the incidence and clinical impact of RBC alloimmunisation in 817 adult MDS (or related disorders) patients enrolled in the South Australian-MDS registry. Methods: Demographic, clinical, laboratory and treatment (including transfusions) details of patients with at least 6-month follow up were analysed. RBC-TD was defined as >1unit of RBC transfusion every 8 weeks over a period of 4 months. Azacitidine, intensive chemotherapy or allogeneic stem cell transplantation were denoted as disease modifying therapies (DMT). Results: Median age at diagnosis was 73 years and 66% were male. During the study, 695 (85%) patients received >1 RBC unit, and 98 developed 175 alloantibodies. Of these, 11 patients developed alloantibodies following MDS-unrelated RBC transfusion well before the MDS diagnosis, and seven developed antibodies before their first documented RBC transfusion. Remaining 80 patients developed alloantibodies following MDS-related RBC transfusion. The cumulative incidence of RBC alloimmunisation with death as competing risk was 11% at 50 months following the first MDS-related RBC transfusion (Fig. 1A). Importantly, 73% and 50% of allo-immunised patients developed alloantibodies during first 20 RBC transfusions and within 6 months of commencement of RBC transfusion, respectively. Of the 98 allo-immunised patients, 50 (51%) developed one alloantibody, while 48 (49%) developed multiple alloantibodies. Rh (93/175; 54%) and Kell (41; 24%) alloantibodies were most frequent followed by Kidd (13, 7.5%) and Lutheran (10, 5.7%). Within Rh system anti-E, anti-C and anti-D were the most frequent. Autoantibodies were detected in significantly more alloimmunised than in non-alloimmunised patients (65% vs. 18%, p 85% autoantibodies occurred within 5 months of alloimmunisation. Though 73% of alloimmunised patients developed alloantibody during their first 20 RBC units, total RBC units transfused were significantly higher in alloimmunised compared to non-alloimmunised patients (90±100 vs. 30±52; p We then evaluated risk factors for alloimmunisation using RSF and R-PART analysis. RBC units transfused before alloantibody formation was the most important predictor of alloimmunisation, followed by RBC-TD status, treatment type and age. A classification tree using RPART suggested that 46% patients who were RBC-TD developed an alloantibody within first 20 units of RBC transfused. Landmark analyses using CRR model both at baseline (using age, sex, WHO subtype, IPSS-R risk groups and type of treatment) and at six months (baseline factors plus number of RBCs transfused within 6 months and RBC-TD status at 6 months) following the start of RBC transfusions were performed. At both time-points, alloimmunisation risk was significantly lower in DMT treated patients (HR -3.04; p=0.0023) and appears unrelated to number of RBC transfusions as patients managed with DMT received significantly more RBC units than patients treated with supportive care (p Conclusion: This study characterises alloimmunisation in a large statewide cohort of MDS patients and demonstrates a significant increase in RBC transfusion requirements following alloimmunisation, most probably due to development of additional alloantibodies and autoantibodies, resulting in subclinical/clinical haemolysis. Use of DMT is associated with lower alloimmunisation risk. Strategies mitigating alloimmunisation risk are critical for optimising RBC-transfusion management. Download : Download high-res image (265KB) Download : Download full-size image Disclosures No relevant conflicts of interest to declare." @default.
• W2969882767 created "2019-08-29" @default.
• W2969882767 creator A5004782158 @default.
• W2969882767 creator A5015935271 @default.
• W2969882767 creator A5018761124 @default.
• W2969882767 creator A5019267283 @default.
• W2969882767 creator A5034211889 @default.
• W2969882767 creator A5034254010 @default.
• W2969882767 creator A5039852798 @default.
• W2969882767 creator A5042393648 @default.
• W2969882767 creator A5047899373 @default.
• W2969882767 creator A5048926164 @default.
• W2969882767 creator A5050862386 @default.
• W2969882767 creator A5054120578 @default.
• W2969882767 creator A5058276561 @default.
• W2969882767 creator A5065007895 @default.
• W2969882767 creator A5066247143 @default.
• W2969882767 creator A5074454599 @default.
• W2969882767 creator A5080144419 @default.
• W2969882767 date "2017-12-07" @default.
• W2969882767 modified "2023-09-28" @default.
• W2969882767 title "Red Cell Alloimmunisation Is Associated with Development of Autoantibodies and Increased Red Cell Transfusion Requirements in Myelodysplastic Syndromes (MDS)" @default.
• W2969882767 doi "https://doi.org/10.1182/blood.v130.suppl_1.2411.2411" @default.
• W2969882767 hasPublicationYear "2017" @default.
• W2969882767 type Work @default.
• W2969882767 sameAs 2969882767 @default.
• W2969882767 citedByCount "0" @default.
• W2969882767 crossrefType "journal-article" @default.
• W2969882767 hasAuthorship W2969882767A5004782158 @default.
• W2969882767 hasAuthorship W2969882767A5015935271 @default.
• W2969882767 hasAuthorship W2969882767A5018761124 @default.
• W2969882767 hasAuthorship W2969882767A5019267283 @default.
• W2969882767 hasAuthorship W2969882767A5034211889 @default.
• W2969882767 hasAuthorship W2969882767A5034254010 @default.
• W2969882767 hasAuthorship W2969882767A5039852798 @default.
• W2969882767 hasAuthorship W2969882767A5042393648 @default.
• W2969882767 hasAuthorship W2969882767A5047899373 @default.
• W2969882767 hasAuthorship W2969882767A5048926164 @default.
• W2969882767 hasAuthorship W2969882767A5050862386 @default.
• W2969882767 hasAuthorship W2969882767A5054120578 @default.
• W2969882767 hasAuthorship W2969882767A5058276561 @default.
• W2969882767 hasAuthorship W2969882767A5065007895 @default.
• W2969882767 hasAuthorship W2969882767A5066247143 @default.
• W2969882767 hasAuthorship W2969882767A5074454599 @default.
• W2969882767 hasAuthorship W2969882767A5080144419 @default.
• W2969882767 hasConcept C120665830 @default.
• W2969882767 hasConcept C121332964 @default.
• W2969882767 hasConcept C126322002 @default.
• W2969882767 hasConcept C159654299 @default.
• W2969882767 hasConcept C163764329 @default.
• W2969882767 hasConcept C203014093 @default.
• W2969882767 hasConcept C2777208419 @default.
• W2969882767 hasConcept C2778430493 @default.
• W2969882767 hasConcept C2780007613 @default.
• W2969882767 hasConcept C2780014101 @default.
• W2969882767 hasConcept C2780817109 @default.
• W2969882767 hasConcept C2911091166 @default.
• W2969882767 hasConcept C61511704 @default.
• W2969882767 hasConcept C71924100 @default.
• W2969882767 hasConcept C88879693 @default.
• W2969882767 hasConceptScore W2969882767C120665830 @default.
• W2969882767 hasConceptScore W2969882767C121332964 @default.
• W2969882767 hasConceptScore W2969882767C126322002 @default.
• W2969882767 hasConceptScore W2969882767C159654299 @default.
• W2969882767 hasConceptScore W2969882767C163764329 @default.
• W2969882767 hasConceptScore W2969882767C203014093 @default.
• W2969882767 hasConceptScore W2969882767C2777208419 @default.
• W2969882767 hasConceptScore W2969882767C2778430493 @default.
• W2969882767 hasConceptScore W2969882767C2780007613 @default.
• W2969882767 hasConceptScore W2969882767C2780014101 @default.
• W2969882767 hasConceptScore W2969882767C2780817109 @default.
• W2969882767 hasConceptScore W2969882767C2911091166 @default.
• W2969882767 hasConceptScore W2969882767C61511704 @default.
• W2969882767 hasConceptScore W2969882767C71924100 @default.
• W2969882767 hasConceptScore W2969882767C88879693 @default.
• W2969882767 hasLocation W29698827671 @default.
• W2969882767 hasOpenAccess W2969882767 @default.
• W2969882767 hasPrimaryLocation W29698827671 @default.
• W2969882767 hasRelatedWork W1178910548 @default.
• W2969882767 hasRelatedWork W1534689507 @default.
• W2969882767 hasRelatedWork W1824435997 @default.
• W2969882767 hasRelatedWork W1864315955 @default.
• W2969882767 hasRelatedWork W1937907644 @default.
• W2969882767 hasRelatedWork W2051153828 @default.
• W2969882767 hasRelatedWork W2117785148 @default.
• W2969882767 hasRelatedWork W2126029428 @default.
• W2969882767 hasRelatedWork W2144736480 @default.
• W2969882767 hasRelatedWork W2145143466 @default.
• W2969882767 hasRelatedWork W2259212152 @default.
• W2969882767 hasRelatedWork W2469491739 @default.
• W2969882767 hasRelatedWork W2564694342 @default.
• W2969882767 hasRelatedWork W2753620413 @default.
• W2969882767 hasRelatedWork W2913254219 @default.
• W2969882767 hasRelatedWork W2939162820 @default.
• W2969882767 hasRelatedWork W3126184322 @default.
• W2969882767 hasRelatedWork W3193228960 @default.
• W2969882767 hasRelatedWork W3202254516 @default.
• W2969882767 hasRelatedWork W993883739 @default.

• next